CN102961399A - Sodium chloride eye drops and preparation method thereof - Google Patents
Sodium chloride eye drops and preparation method thereof Download PDFInfo
- Publication number
- CN102961399A CN102961399A CN2012104921529A CN201210492152A CN102961399A CN 102961399 A CN102961399 A CN 102961399A CN 2012104921529 A CN2012104921529 A CN 2012104921529A CN 201210492152 A CN201210492152 A CN 201210492152A CN 102961399 A CN102961399 A CN 102961399A
- Authority
- CN
- China
- Prior art keywords
- eye drop
- sodium chloride
- injection
- water
- hypromellose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 title claims abstract description 68
- 239000003889 eye drop Substances 0.000 title claims abstract description 45
- 239000011780 sodium chloride Substances 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 229940012356 eye drops Drugs 0.000 title abstract description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 27
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 27
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000008215 water for injection Substances 0.000 claims abstract description 21
- 239000006174 pH buffer Substances 0.000 claims abstract description 5
- 229960003943 hypromellose Drugs 0.000 claims description 24
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 15
- 229910021538 borax Inorganic materials 0.000 claims description 14
- 239000004327 boric acid Substances 0.000 claims description 14
- 239000004328 sodium tetraborate Substances 0.000 claims description 14
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 14
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 13
- 230000000844 anti-bacterial effect Effects 0.000 claims description 12
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 11
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 11
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 4
- 239000003607 modifier Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims description 2
- -1 antibacterial Chemical compound 0.000 claims description 2
- 229960004926 chlorobutanol Drugs 0.000 claims description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 239000004334 sorbic acid Substances 0.000 claims description 2
- 235000010199 sorbic acid Nutrition 0.000 claims description 2
- 229940075582 sorbic acid Drugs 0.000 claims description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 2
- 229940033663 thimerosal Drugs 0.000 claims description 2
- 125000005619 boric acid group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 208000005494 xerophthalmia Diseases 0.000 abstract description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 3
- 239000000022 bacteriostatic agent Substances 0.000 abstract 1
- 230000005923 long-lasting effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 10
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 5
- 210000001138 tear Anatomy 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 4
- 239000000607 artificial tear Substances 0.000 description 3
- 206010013774 Dry eye Diseases 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides sodium chloride eye drops containing hydroxypropyl methylcellulose and a preparation method of the sodium chloride eye drops. The eye drops comprise sodium chloride, hydroxypropyl methylcellulose and water for injection, and a bacteriostatic agent and an acid-base regulator can be added. The eye drops have the following prescription and amount based on 100ml: 0.45-0.75g of sodium chloride, 0.03-0.06g of hydroxypropyl methylcellulose, a pH buffer system and the water for injection. The eye drops are long-lasting in function, obvious in effect of treating xerophthalmia, safe and small in side effect.
Description
Technical field
The present invention relates to a kind of sodium chloride eye drop and preparation method thereof, especially relate to the sodium chloride eye drop that contains hypromellose, belong to field of pharmaceutical preparations.
Background technology
Xerophthalmia is a kind of common ophthalmic diseases; be again the angle conjunctival xerosis; refer to that tear matter that any reason causes or amount are unusual or kinetics is unusual, cause tear film stability decline, and with ophthalmic uncomfortable and (or) general name of the various diseases of eye table organization characteristics of lesion.Along with TV play, computer etc. is widely used in human daily life, aged tendency of population increases gradually in recent years, and the incidence rate of xerophthalmia rises year by year, badly influences the normal development of teenager vision and the usefulness eye health of middle-aged and elderly people.
The primary treatment measure of xerophthalmia is to replenish tear, i.e. local humidity and the lubricating ability of using the artificial tears to improve ocular surface.
External artificial tears has tens of kinds more than, generally by the ingredients that contains some inorganic salts and high molecular polymer and stimulate lacrimal secretion.But most artificial tearss are unstable to the effect for the treatment of of dry eye, and the persistent period is short, and the domestic adjuvant such as antibacterial that contains has certain toxic action to eye table epithelium more.At present, commercially available eye drop antibacterial mostly is benzalkonium chloride, and it can destroy the tight connecting band between corneal epithelial cell, the cornea permeability is increased, can also be combined with the lipid film of corneal epithelial cell film, cell membrane be increased the permeability of water and various ions, and reduce artificial tears's curative effect.
In recent years, though the existing eye drop that can increase moistening effect on the market, such as: sodium hyaluronate eye drops or contain the eye drop of hyaluronic acid sodium, but hyaluronic acid sodium is unstable under light, heat, easily degraded, long preservation at room temperature, simultaneously, hyaluronic acid sodium is a kind of biomacromolecule mucopolysaccharide, easy contaminated long bacterium.In view of the defective of above eye drop, be necessary to develop a kind of steady quality, can play long-acting moisturizing again, easing eyes is dry and astringent, simultaneously, the eye drop that side effect is again little.
Summary of the invention
The object of the invention is exactly to solve the defective that prior art exists, and provides a kind of steady quality, long-acting moisturizing, the eye drop that side effect is little.The sodium chloride eye drop that contains hypromellose provided by the invention just can overcome the above problems well.
The object of the present invention is to provide a kind of sodium chloride eye drop that contains hypromellose.
Another object of the present invention is to provide the preparation method of the sodium chloride eye drop that contains hypromellose.
The present invention relates to a kind of sodium chloride eye drop that contains hypromellose, it is characterized in that, described eye drop contains sodium chloride 0.45～0.75g in 100ml, hypromellose 0.03～0.06g, pH buffer system, water for injection.
Above-mentioned pH buffer system is preferably boric acid and Borax, and its consumption is respectively 0.53g and 0.05g.
The present invention relates to a kind of sodium chloride eye drop that contains hypromellose, it is characterized in that, described eye drop contains sodium chloride 0.55g in 100ml, hypromellose 0.05g, boric acid 0.53g, Borax 0.05g, water for injection.
The above-mentioned sodium chloride eye drop that contains hypromellose also contains acid-base modifier, so that the pH value of final solution is 6.0～8.5, and preferred 6.5～7.5.
Above-mentioned acid-base modifier is selected from: one or more of hydrochloric acid, citric acid, sodium hydroxide, potassium hydroxide and sodium citrate.
Preferably, the above-mentioned sodium chloride eye drop that contains hypromellose also contains antibacterial, and its content is 0.01g～0.5g
Above-mentioned antibacterial is selected from: one or more of chlorobutanol, thimerosal, sorbic acid, benzalkonium chloride, methyl hydroxybenzoate, ethyl hydroxybenzoate, propyl hydroxybenzoate and butyl hydroxybenzoate, and preferred ethyl hydroxybenzoate, its consumption is 0.03g.
Select hypromellose and sodium chloride to be used among the present invention, make eye drop have extraordinary moistening effect, the weight proportion of preferred hypromellose and sodium chloride is: 3: 55～6: 55
Preparation method of the present invention is characterized in that, the method may further comprise the steps:
(1) in advance that the hypromellose adding of recipe quantity is an amount of
The water for injection dissolvingFor subsequent use.
(2) take by weighing respectively sodium chloride, antibacterial, boric acid and the Borax of recipe quantity, each adds an amount of water for injection, sterilizes after mixing.
(3) antibacterial after the sterilization in the above-mentioned steps (2) is for subsequent use after with an amount of water for injection heating for dissolving.
(4) sodium chloride after the sterilization in the above-mentioned steps (2), boric acid, Borax are added in the antibacterial solution of placing room temperature in the above-mentioned steps (3), stir and make dissolving, mix homogeneously.
(5) with the solution mix homogeneously in step (1) and (4), add residue water for injection and mix homogeneously.
(6) regulate medicinal liquid pH value to 6.5～7.5 with potassium hydroxide or the 0.1mol/L hydrochloric acid solution of 0.1mol/L, with 0.22 μ m filter membrane the medicinal liquid for preparing is carried out aseptic filtration, take a sample to check after filtration finishes appearance character, pH value, qualified rear fill.
Because the utilization of technique scheme, the present invention compared with prior art has the following advantages:
(1) but contain hypromellose the sodium chloride eye drop long period stick to the corneal epithelium surface, play keeping the skin wet and protective effect, and meet the osmotic pressure of human body tear, viscosity and electrolyte concentration etc.
(2) the pH scope of general eye drop is all 6～8, and it is uncomfortable that too high (pH is greater than 9) or excessively low (pH is less than 5) can make eye produce.Therefore, the pH that determines eye drop is: 6.5～7.5.The present invention adopts boric acid and Borax buffer system, can keep the pH of medicinal liquid at 6.5-7.5, and borate also has certain bacteriostasis simultaneously.
(3) eye drop steady quality of the present invention is fit at normal temperatures long preservation.
The specific embodiment:
Embodiment 1:
In 100ml, the preparation eye drop contains:
Sodium chloride 0.55g, hypromellose 0.03g, boric acid 0.53g, Borax 0.05g, ethyl hydroxybenzoate 0.03g, water for injection.
Preparation method may further comprise the steps:
(1) gets in advance the 0.05g hypromellose and join in an amount of water for injection, dissolve for subsequent use.
(2) take by weighing respectively sodium chloride 0.55g, ethyl hydroxybenzoate 0.03g, boric acid 0.53g and Borax 0.05g, each adds an amount of water for injection, stirs to make and puts into high-pressure sterilizing pot (121 ℃, 30 minutes) in the mix homogeneously rear-mounted triangular beaker and sterilize.
(3) with the ethyl hydroxybenzoate after the above-mentioned sterilization with an amount of water for injection heating for dissolving.
(4) sodium chloride after the above-mentioned sterilization, boric acid, Borax are added in the ethyl hydroxybenzoate solution of the placement room temperature in above-mentioned (3), stir and make dissolving, mix homogeneously.
(5) with the solution mix homogeneously in step (1) and (4), add residue water for injection and mix homogeneously.
(6) regulate medicinal liquid pH value to 6.5～7.5 with potassium hydroxide or the 0.1mol/L hydrochloric acid solution of 0.1mol/L, with 0.22 μ m filter membrane the medicinal liquid for preparing is carried out aseptic filtration, take a sample to check after filter finishing appearance character, pH value, osmotic pressure, visible foreign matters, qualified rear fill.
Embodiment 2:
In 100ml, the preparation eye drop contains:
Sodium chloride 0.55g, hypromellose 0.05g, boric acid 0.53g, Borax 0.05g, ethyl hydroxybenzoate 0.03g, water for injection.
Its preparation method is with above-mentioned embodiment 1.
Embodiment 3:
In 100ml, the preparation eye drop contains:
Sodium chloride 0.55g, hypromellose 0.06g, boric acid 0.53g, Borax 0.05g, ethyl hydroxybenzoate 0.03g, water for injection.
Its preparation method is with above-mentioned embodiment 1.
Each embodiment sample and the eye drop that does not add the blank of hypromellose and be added with hyaluronate sodium are carried out the test of moisturizing rate, and result of the test is as follows:
The moisturizing rate of different wetting agents is with the variation of standing time
For guaranteeing steady quality of the present invention, safety, so carried out medicine stability test (accelerating and long term test).Test example is as follows:
One, accelerated test
1.40 ℃ ± 2 ℃, relative humidity RH75% ± 5%, result of the test is as follows:
2.40 ℃ ± 2 ℃, relative humidity 25% ± 5%, result of the test is as follows:
Two, long term test
1.25 ℃ ± 2 ℃, relative humidity 60% ± 10%, result of the test is as follows:
2.25 ℃ ± 2 ℃, relative humidity 40% ± 5%, result of the test is as follows:
Three, conclusion
The sample that the present invention produces with embodiment is in 40 ℃ ± 2 ℃, relative humidity 75% ± 5%, and 40 ℃ ± 2 ℃, to place 6 months under relative humidity 25% ± 5% condition, indices is good, conforms to quality requirements.In 25 ℃ ± 2 ℃, relative humidity 60% ± 10%, 25 ℃ ± 2 ℃, to place 2 years under relative humidity 40% ± 5% condition, significant change does not all occur in outward appearance, pH, viscosity, sodium chloride content and ethyl hydroxybenzoate content, conforms to quality requirements.
Claims (9)
1. a sodium chloride eye drop that contains hypromellose is characterized in that, described eye drop contains sodium chloride 0.45～0.75g in 100ml, hypromellose 0.03～0.06g, pH buffer system, water for injection.
2. eye drop according to claim 1 is characterized in that, the pH buffer system is boric acid and Borax.
3. eye drop according to claim 1, the weight proportion that it is characterized in that hypromellose and sodium chloride is 3: 55～6: 55.
4. eye drop according to claim 1 is characterized in that, described eye drop contains sodium chloride 0.55g in 100ml, hypromellose 0.05g, boric acid 0.53g, Borax 0.05g, water for injection.
5. the described eye drop of any one is characterized in that also containing acid-base modifier according to claim 1-4, so that the pH value of final solution is 6.0～8.5, and preferred 6.5～7.5.
6. eye drop according to claim 5, described acid-base modifier is selected from one or more of hydrochloric acid, citric acid, sodium hydroxide, potassium hydroxide and sodium citrate.
7. eye drop according to claim 6 is characterized in that it also contains antibacterial, and its content is 0.01g～0.5g.
8. eye drop according to claim 7 is characterized in that described antibacterial is selected from the one or more combination of chlorobutanol, thimerosal, sorbic acid, benzalkonium chloride, methyl hydroxybenzoate, ethyl hydroxybenzoate, propyl hydroxybenzoate and butyl hydroxybenzoate, preferred ethyl hydroxybenzoate.
9. the preparation method of described eye drop according to claim 8 is characterized in that the method may further comprise the steps:
(1) in advance that the hypromellose adding of recipe quantity is an amount of
The water for injection dissolvingFor subsequent use.
(2) take by weighing respectively sodium chloride, antibacterial, boric acid and the Borax of recipe quantity, each adds an amount of water for injection, sterilizes after mixing.
(3) antibacterial after the sterilization in the above-mentioned steps (2) is for subsequent use after with an amount of water for injection heating for dissolving.
(4) sodium chloride after the sterilization in the above-mentioned steps (2), boric acid, Borax are added in the antibacterial solution of placing room temperature in the above-mentioned steps (3), stir and make dissolving, mix homogeneously.
(5) with the solution mix homogeneously in step (1) and (4), add residue water for injection and mix homogeneously.
(6) regulate medicinal liquid pH value to 6.5～7.5 with potassium hydroxide or the 0.1mol/L hydrochloric acid solution of 0.1mol/L, with 0.22 μ m filter membrane the medicinal liquid for preparing is carried out aseptic filtration, take a sample to check after filtration finishes appearance character, pH value, qualified rear fill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210492152.9A CN102961399B (en) | 2012-11-28 | 2012-11-28 | Sodium chloride eye drops and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210492152.9A CN102961399B (en) | 2012-11-28 | 2012-11-28 | Sodium chloride eye drops and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102961399A true CN102961399A (en) | 2013-03-13 |
| CN102961399B CN102961399B (en) | 2014-09-10 |
Family
ID=47792018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210492152.9A Active CN102961399B (en) | 2012-11-28 | 2012-11-28 | Sodium chloride eye drops and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102961399B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109439469A (en) * | 2018-12-27 | 2019-03-08 | 江苏海伦隐形眼镜有限公司 | A kind of dissolving method of cellulose, cellulose-containing clear transparent solutions and its application |
| CN114848670A (en) * | 2022-05-26 | 2022-08-05 | 青岛博益特生物材料股份有限公司 | Eye drops and preparation method thereof |
| CN115093486A (en) * | 2022-07-13 | 2022-09-23 | 上海卫康光学眼镜有限公司 | Hydroxypropyl methylcellulose HPMC (hydroxy propyl methyl cellulose) dissolving method |
| CN115702879A (en) * | 2021-08-06 | 2023-02-17 | 成都康弘药业集团股份有限公司 | Eye drops of atropine sulfate |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102100693A (en) * | 2009-12-16 | 2011-06-22 | 沈阳兴齐制药有限公司 | Artificial tears including carnosine and preparation method thereof |
| CN102188368A (en) * | 2011-04-15 | 2011-09-21 | 苏州太湖美药业有限公司 | Preparation technology of compound sodium chloride eye drop solution |
| CN102283805A (en) * | 2011-06-29 | 2011-12-21 | 扬子江药业集团有限公司 | Method for preparing eye drops containing non-ionic cellulose derivatives |
-
2012
- 2012-11-28 CN CN201210492152.9A patent/CN102961399B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102100693A (en) * | 2009-12-16 | 2011-06-22 | 沈阳兴齐制药有限公司 | Artificial tears including carnosine and preparation method thereof |
| CN102188368A (en) * | 2011-04-15 | 2011-09-21 | 苏州太湖美药业有限公司 | Preparation technology of compound sodium chloride eye drop solution |
| CN102283805A (en) * | 2011-06-29 | 2011-12-21 | 扬子江药业集团有限公司 | Method for preparing eye drops containing non-ionic cellulose derivatives |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109439469A (en) * | 2018-12-27 | 2019-03-08 | 江苏海伦隐形眼镜有限公司 | A kind of dissolving method of cellulose, cellulose-containing clear transparent solutions and its application |
| CN115702879A (en) * | 2021-08-06 | 2023-02-17 | 成都康弘药业集团股份有限公司 | Eye drops of atropine sulfate |
| CN114848670A (en) * | 2022-05-26 | 2022-08-05 | 青岛博益特生物材料股份有限公司 | Eye drops and preparation method thereof |
| CN115093486A (en) * | 2022-07-13 | 2022-09-23 | 上海卫康光学眼镜有限公司 | Hydroxypropyl methylcellulose HPMC (hydroxy propyl methyl cellulose) dissolving method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102961399B (en) | 2014-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008001872A1 (en) | Ophthalmic composition containing alginic acid or salt thereof | |
| CN101312711A (en) | Pharmaceutical composition free from dexpanthenol, calcium ions, and phosphate, and use of calcium chelating agent and ophthalmologically compatible viscosity regulator | |
| US20210259961A1 (en) | Pharmaceutical composition for preventing and treating nitm and medical use thereof | |
| CN104981234A (en) | Artificial tears comprising sodium hyaluronate and carboxymethylcellulose | |
| CN102961399B (en) | Sodium chloride eye drops and preparation method thereof | |
| CN110974970A (en) | Compound pharmaceutical composition eye drops, preparation method and application thereof | |
| JP2022001579A (en) | Eye drops for nonionic silicone hydrogel contact lenses | |
| US9351990B2 (en) | Hypertonic dextran solution and methods of treating and preventing recurrent corneal erosion | |
| JP2018177820A (en) | Aqueous ophthalmic composition | |
| CN112426405A (en) | Pharmaceutical composition for preventing and controlling myopia development, eye drops and preparation method and application thereof | |
| JP2017066065A (en) | Ophthalmic composition | |
| CN102697713B (en) | Sodium hyaluronate eye drops and a preparation method thereof | |
| CN108261390A (en) | A kind of brinzolamide Brimonidine eye drops and preparation method thereof | |
| CN111803441A (en) | Sodium hyaluronate eye drops containing 0.01% atropine and preparation method thereof | |
| CN105232454B (en) | High-fidelity chitosan sodium hyaluronate eye drops and preparation method thereof | |
| CN104622800A (en) | Bendazac lysine eye drop and preparation method thereof | |
| CN110327404A (en) | A kind of xerophthalmia moisturizing spray and preparation method thereof | |
| CN108853556A (en) | A kind of contact lens,hard care composition and preparation method thereof containing sodium lactate | |
| CN102579492A (en) | Sodium hyaluronate eyedrop containing deproteinized calf blood extractive and preparation method thereof | |
| CN102188368A (en) | Preparation technology of compound sodium chloride eye drop solution | |
| CN101579357A (en) | Ready-to-use fel ursi ophthalmic gel | |
| EP2800573B1 (en) | Ophthalmic composition | |
| RU2755298C1 (en) | Contact lens care solution | |
| CA2835013C (en) | Eye drops for treatment of conjunctivochalasis | |
| CN102973594A (en) | Ophthalmic preparation containing oxygen micro-capsules and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 750002 the Ningxia Hui Autonomous Region street, Jinfeng District, Yinchuan City Fu Ning Lane No. 57 Patentee after: Ningxia Kang Ya pharmaceutical Limited by Share Ltd Address before: 750002 No. 6 road, hi tech Industrial Development Zone, the Ningxia Hui Autonomous Region, Yinchuan Patentee before: Kangya Pharmaceutical Industry Co., Ltd., Ningxia |